nach oben

Calcified Tissue International

Erschienen in:

01.03.2013 | Review

The Relationship Among Hypertension, Antihypertensive Medications, and Osteoporosis: A Narrative Review

verfasst von: Katarina Ilić, Nevena Obradović, Nada Vujasinović-Stupar

Erschienen in: Calcified Tissue International | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Osteoporosis and hypertension are two frequent diseases among the aging population that share a similar etiopathology and often coexist. Moreover, treatment of hypertension affects bone mineral density and, therefore, can worsen osteoporosis. This narrative review considers the influence of the main etiologic factors that contribute to the development of hypertension and osteoporosis and examines the effect of the most often used antihypertensives on bones. A computerized literature search of relevant English publications regarding the etiology of hypertension and osteoporosis as well as the impact of antihypertensives on osteoporosis from 1996 to 2011 was completed in October 2011. The latest update in the search was performed from May to June 2012. The most relevant nongenetic factors in the etiology of osteoporosis and hypertension are low calcium intake, vitamin D and vitamin K deficiency, high consumption of sodium salt, and the effects of different forms of nitric oxide. Thiazide diuretics are the only antihypertensives that have a positive influence on bone mineral density. For other antihypertensive drugs, the data are conflicting, indicating that they may have a potentially negative or positive influence on bone mineral density and fracture risk reduction. Some studies did not find a correlation between the use of antihypertensives and bone mineral density. Due to the frequent coexistence of hypertension and osteoporosis, when selecting long-term antihypertensive therapy the potential effects of antihypertensive drugs on development, worsening, or improvement of osteoporosis should also be considered.

Pérez-Castrillόn JL, Justo I, Sanz-Cantalapiedra A, Pueyo C, Hernández G, Dueñas A (2005) Effect of the antihypertensive treatment on the bone mineral density and osteoporotic fracture. Curr Hypertens Rev 1:61–66CrossRef

Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38:S4–S9PubMedCrossRef

European Society for Clinical and Economic Aspect of Osteoporosis and Osteoarthritis (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428CrossRef

International Osteoporosis Foundation. Osteoporosis general. http://www.iofbonehealth.org/facts-and-statistics.html. Accessed 14 July 2009

Metz JA, Morris CD, Roberts LA, McClung MR, McCarron DA (1999) Blood pressure and calcium intake are related to bone density in adult males. Br J Nutr 81:383–388PubMed

Cappucio FP, Meilahn E, Zmuda JM, Cauley JA (1999) High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet 354:971–975CrossRef

Vestergaard P, Rejnmark L, Mosekilde L (2009) Hypertension is a risk factor for fractures. Calcif Tissue Int 84:103–111PubMedCrossRef

Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581–589PubMedCrossRef

Lynn H, Kwok T, Wong SYS, Woo J, Leung PC (2006) Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38:584–588PubMedCrossRef

10.

Ott SM, LaCroix AZ, Scholes D, Ichikawa L, Wu K (2008) Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons. Osteoporos Int 19:1315–1322PubMedCrossRef

11.

Rang HP et al. (2012) Bone metabolism. In: Rang and Dale`s pharmacology. 7th ed, Churchill Livingstone, Elsevier, Philadelphia, pp 432–441

12.

Power ML, Heaney RP, Kalkwarf HJ et al (1999) The role of calcium in health and disease. Am J Obstet Gynecol 181:1560–1569PubMedCrossRef

13.

Zemel MB (2001) Calcium modulation of hypertension and obesity: mechanisms and implications. J Am Coll Nutr 20:428S–435SPubMed

14.

McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR (2004) Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 23(1):1–10PubMedCrossRef

15.

Zitterman A, Schleithoff SS, Koerfer R (2005) Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 94:483–492CrossRef

16.

Lips P (2006) Vitamin D physiology. Prog Biophys Mol Biol 92:4–8PubMedCrossRef

17.

Boonen S, Vanderschueren D, Haentjens P, Lips P (2006) Calcium and vitamin D in the prevention and treatment of osteoporosis—a clinical update. J Intern Med 259:539–552PubMedCrossRef

18.

Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Andersen H et al (2000) Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int 66(6):419–424PubMedCrossRef

19.

Mosekilde L (2005) Vitamin D and the elderly. Clin Endocrinol (Oxf) 62:265–281CrossRef

20.

London GM, Guérin AP, Verbeke FH et al (2007) Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18:613–620PubMedCrossRef

21.

Braam LA, Knapen MH, Geusens P et al (2003) Vitamin K₁ supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int 73:21–26PubMedCrossRef

22.

Vermeer C, Shearer M, Zittermann A et al (2004) Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr 43:325–335PubMedCrossRef

23.

Knapen MH J, Schurgers L, Vermeer C (2007) Vitamin K₂ supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int 18:963–972PubMedCrossRef

24.

Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP (2009) Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 20:197–207PubMedCrossRef

25.

Cranenburg CME, Schurgers JL, Vermeer C (2007) Vitamin K: The coagulation vitamin that became omnipotent. Thromb Haemost 98:120–125PubMed

26.

Adams J, Pepping J (2005) Vitamin K in the treatment and prevention of osteoporosis and arterial calcification. Am J Health Syst Pharm 62

27.

Cockayne S, Adamson J, Lanham-New S, Shearer M, Gilbody S, Torgerson D (2006) Vitamin K and the prevention of fractures—systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166:1256–1261PubMedCrossRef

28.

Heaney PR (2006) Role of dietary sodium in osteoporosis. J Am Coll Nutr 25(3):271S–276SPubMed

29.

Woo J, Kwok T, Leung J, Tang N (2009) Dietary intake, blood pressure and osteoporosis. J Hum Hypertens 23:451–455PubMedCrossRef

30.

Karppanen H, Karppanen P, Mervaala E (2005) Why and how to implement sodium, potassium, calcium, and magnesium changes in food items and diets? J Hum Hypertens 19:S10–S19PubMedCrossRef

31.

Rang HP et al. (2012) The vascular system. In: Rang and Dale`s Pharmacology. 7th ed, Churchill Livingstone, Elsevier, Philadelphia, pp 265–282

32.

Khosla S (2011) Is nitroglycerin a novel and inexpensive treatment for osteoporosis? JAMA 305(8):826–827PubMedCrossRef

33.

Jamal SA, Hamilton CJ, Eastell R, Cummings SR (2011) Effect of nitroglycerin ointment on bone density and strength in postmenopausal women. JAMA 05(8):800–807CrossRef

34.

Rejnmark L, Vestergaard P, Mosekilde L (2006) Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res 21(11):1811–1817PubMedCrossRef

35.

Wimalawansa SJ (2000) Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res 15(11):2240–2244PubMedCrossRef

36.

Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR (2009) Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab 94(9):3356–3364PubMedCrossRef

37.

Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J Bone Miner Res 19:19–24PubMedCrossRef

38.

Shih TTF, Chang CJ, Tseng WYI et al (2004) Effect of calcium channel blockers on vertebral bone marrow perfusion of the lumbar spine. Radiology 231:24–30PubMedCrossRef

39.

Žofkova I, Kancheva RL (1995) The effect of nifedipine on serum parathyroid hormone and calcitonin in postmenopausal women. Life Sci 57(11):1087–1096PubMedCrossRef

40.

Rejnmark L, Vestergaard P, Mosekilde L (2006) Fracture risk in patients treated with loop diuretics. J Intern Med 259:117–124PubMedCrossRef

41.

Rejnmark L, Vestergaard P, Kassem M et al (2004) Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 75:365–372PubMedCrossRef

42.

Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L (2006) Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 21:163–170PubMedCrossRef

43.

Reid IR, Gamble GD, Grey AB et al (2005) β-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20:613–618PubMedCrossRef

44.

Zacharieva S, Shigarminova R, Nachev E et al (2003) Effect of amlodipine and hormone replacement therapy on blood pressure and bone markers in menopause. Methods Find Exp Clin Pharmacol 25(3):209PubMedCrossRef

45.

Hajjar I (2005) Postural blood pressure changes and orthostatic hypotension in the elderly patient: impact of antihypertensive medications. Drugs Aging 22(1):55–68PubMedCrossRef

46.

Sowers MR, Clark MK, Jannausch ML, Wallace RB (1993) Body size, estrogen use and thiazide diuretic use affect 5-year radial bone loss in postmenopausal women. Osteoporos Int 3:314–321PubMedCrossRef

47.

Cauley JA, Cummings SR, Seeley DG et al (1993) Effects of thiazide diuretic therapy on bone mass, fractures, and falls. Ann Intern Med 118:666–673PubMed

48.

Jones G, Nguyen Tuan, Sambrook PN, Eisman JA (1995) Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res 10:106–111PubMed

49.

LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 133:516–526PubMed

50.

Schoofs MWCJ, van der Klift M, Hofman A et al (2003) Thiazide diuretics and the risk for hip fracture. Ann Intern Med 139:476–482PubMed

51.

Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR (2007) The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int 18:479–486PubMedCrossRef

52.

Cruz DN (2001) The renal tubular Na–Cl co-transporter (NCCT): a potential genetic link between blood pressure and bone density? Nephrol Dial Transpl 16:691–694CrossRef

53.

Alkalosis, metabolic. http://emedicine.medscape.com/article/906819-overview. Accessed 24 Oct 2009

54.

Haque SF, Ahmad M, Khan AU, Gupta V, Khan AS (2011) Angiotensin converting enzyme insertion/deletion gene polymorphism and genomic sequence in diabetic nephropathy. Biomed Res 22(2):173–177

55.

Schlienger RG, Kraenzlin ME, Jick SS, Meier CR (2004) Use of β-blockers and risk of fractures. JAMA 292:1326–1332PubMedCrossRef

56.

Takeda S (2009) Osteoporosis: a neurosceletal disease? Int J Biochem Cell Biol 41:455–459PubMedCrossRef

57.

Wiens M, Etminan M, Gill SS, Takkouche B (2006) Effects of antihypertensive drug treatment on fracture outcomes: a meta-analysis of observational studies. J Intern Med 260:350–362PubMedCrossRef

58.

Souverein PC, Van Staa TP, Egberts ACG, de la Rosette MCH, Cooper C, Leufkens HGM (2003) Use of α-blockers and the risk of hip/femur fractures. J Intern Med 254:548–554PubMedCrossRef

Titel: The Relationship Among Hypertension, Antihypertensive Medications, and Osteoporosis: A Narrative Review
verfasst von: Katarina Ilić
Nevena Obradović
Nada Vujasinović-Stupar
Publikationsdatum: 01.03.2013
Verlag: Springer-Verlag
Erschienen in: Calcified Tissue International / Ausgabe 3/2013
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-012-9671-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Relationship Among Hypertension, Antihypertensive Medications, and Osteoporosis: A Narrative Review

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Effects of Odanacatib on Bone Mineralization Density Distribution in Thoracic Spine and Femora of Ovariectomized Adult Rhesus Monkeys: A Quantitative Backscattered Electron Imaging Study

Endothelial Nitric Oxide Synthase is Not Essential for Nitric Oxide Production by Osteoblasts Subjected to Fluid Shear Stress In Vitro

Effects of Zoledronate on Irradiated Bone In Vivo: Analysis of the Collagen Types I, V and Their Cross-links Lysylpyridinoline, Hydroxylysylpyridinoline and Hydroxyproline

Glucocorticoid-Induced Changes in the Geometry of Osteoclast Resorption Cavities Affect Trabecular Bone Stiffness

Long-Term Bone Density Evaluation in Cerebrotendinous Xanthomatosis: Evidence of Improvement after Chenodeoxycholic Acid Treatment

The Role of Bone Marrow-Derived Cells During the Bone Healing Process in the GFP Mouse Bone Marrow Transplantation Model

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin